Department of Nephrology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China; Department of Nephrology, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Department of Nephrology, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
J Ren Nutr. 2021 Mar;31(2):199-205. doi: 10.1053/j.jrn.2020.04.008. Epub 2020 Jun 30.
Alterations in the gut microbiota and host responses have been implicated in the progression of end-stage renal disease, increased cardiovascular risk, uremic toxicity, and inflammation. The purpose of this study was to evaluate the clinical efficacy of probiotics on malnutrition and health-related quality of life in patients undergoing peritoneal dialysis (PD).
A total of 116 patients undergoing PD were randomly divided into an intervention group (n = 58) and a control group (n = 58). The intervention group received a daily dose of probiotics (1 × 10 CFU/day, i.e., 2 capsules, tid) for 2 months, while the control group did not receive probiotics during the same period. Biochemical indicators, physical measurements, and scores on the SF-36 were measured before and 2 months after the intervention.
A total of 98 patients completed the study (50 in the intervention group and 48 in the control group). Among patients receiving probiotics, the levels of high-sensitivity C-reactive protein and interleukin-6 decreased after 2 months of treatment, while the serum albumin levels, upper arm circumference, and triceps skinfold thickness increased significantly. The probiotic group had higher scores on the physical functioning and social functioning domains than the control group after 2 months.
Probiotics could significantly decrease the serum levels of high-sensitivity C-reactive protein and interleukin-6 and increase the serum albumin levels, upper arm circumference, and triceps skinfold thickness in patients undergoing PD. As a result, malnutrition and health-related quality of life partially improved after probiotic supplementation in patients undergoing PD.
肠道微生物群的改变和宿主反应与终末期肾病的进展、心血管风险增加、尿毒症毒性和炎症有关。本研究旨在评估益生菌对腹膜透析（PD）患者营养不良和健康相关生活质量的临床疗效。
共 116 例 PD 患者随机分为干预组（n=58）和对照组（n=58）。干预组每天服用益生菌（1×10 CFU/天，即 2 粒，tid）2 个月，而对照组在同一时期未服用益生菌。干预前后测量生化指标、身体测量和 SF-36 评分。
共有 98 例患者完成了研究（干预组 50 例，对照组 48 例）。在接受益生菌治疗的患者中，2 个月后高敏 C 反应蛋白和白细胞介素 6 的水平降低，而血清白蛋白水平、上臂围和三头肌皮褶厚度显著增加。2 个月后，益生菌组在身体功能和社会功能领域的评分高于对照组。
益生菌可显著降低 PD 患者血清高敏 C 反应蛋白和白细胞介素 6 水平，增加血清白蛋白水平、上臂围和三头肌皮褶厚度。因此，PD 患者补充益生菌后，营养不良和健康相关生活质量部分得到改善。
